Pharmacology Watch
RSSArticles
-
Remibrutinib Tablets (Rhapsido)
The U.S. Food and Drug Administration has approved a second Bruton’s tyrosine kinase inhibitor (BTKi), remibrutinib, for the treatment of chronic spontaneous urticaria (CSU) in adults who remain symptomatic despite antihistamine treatment. The first BTKi, rilzabrutinib (Wayrilz), was approved for chronic immune thrombocytopenia. Remibrutinib is distributed by Novartis Pharmaceuticals Corporation as Rhapsido.
-
FDA Actions
In this section: The agency approves a new drug for prostate cancer and expands the indication for a non-small cell lung cancer treatment.
-
Influenza A Renders This Year’s Flu Vaccine Ineffective
This year’s flu vaccine was only 36% effective, according to the CDC.
-
What About Aspirin for PCI Patients?
Should clinicians continue using aspirin for patients with prior percutaneous coronary intervention who are undergoing noncardiac surgery? The answer appears to be yes based on the results of a new study from Canada.
-
Comparing Treatments for Cancer-associated VTE
Researchers have determined that edoxaban was noninferior to dalteparin regarding the composite outcome of recurrent VTE or major bleeding, although recurrent VTE was lower and bleeding was higher with edoxaban.
-
Aspirin Matches Xarelto Efficacy Regarding VTE Prophylaxis After Knee or Hip Surgery
The authors of a recent study concluded that among hip or knee arthroplasty patients who receive five days of postoperative rivaroxaban, extended prophylaxis with aspirin was not significantly different from rivaroxaban in the prevention of symptomatic venous thromboembolism.
-
FDA Actions
In this section: The agency tackles loperamide abuse, approves new breast cancer treatment, updates guidance on opioid cough and cold medications, promotes new opportunities to battle the opioid epidemic, and issues new indication for an irritable bowel drug.
-
Oral Medications for Toenail Fungus
Researchers compared terbinafine to placebo and other oral antifungals, including the azole antifungals (ketoconazole, itraconazole, and fluconazole) and Griseofulvin.
-
Fish Oil for Heart Patients?
The authors of a recent meta-analysis concluded that omega-3 fatty acids produced no effects on fatal or nonfatal coronary heart disease, nor on any major vascular events.
-
Alzheimer’s Drug Proven Ineffective
A once-promising drug produces disappointing results in a recent trial, to the dismay of researchers, patients, and families still searching for a cure.